Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05101629
Title Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Indications

hepatocellular carcinoma

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.